CAR-T cell therapies to pave way for drug-free remission in lupus care

14 November 2024

Pharma major Bristol Myers Squibb (NYSE: BMY) and US biotech Cabaletta Bio are set to present promising Phase I data on CD19-directed CAR-T therapies for severe, refractory lupus at the American College of Rheumatology 2024.

BMS’ CC-97540 and Cabaletta Bio’s CABA-201 showed significant efficacy, offering new hope for severe, refractory lupus and other challenging autoimmune diseases. Both studies highlight CAR T’s potential to achieve lasting drug-free remission, marking a ground-breaking advancement in the future treatment of lupus, says pharma analytics company GlobalData.

CC-97540 (BMS-986353) is an investigational CAR T therapy produced with a next-generation NEX-T manufacturing process, while CABA-201 is a fully human CAR-T therapy targeting immune-mediated conditions like systemic lupus erythematosus (SLE) and immune-mediated necrotizing myopathy (IMNM).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK